- Patients with metastatic upper tract urothelial cancer (UTUC) who undergo cytoreductive surgery (CRS) after chemotherapy experience an OS benefit vs those without surgery.
Why this matters
- Data are limited regarding management of patients with metastatic UTUC treated with chemotherapy.
- Study of 1182 patients with metastatic UTUC from the National Cancer Database treated with chemotherapy with or without CRS, 2004-2016.
- Funding: None disclosed.
- 29.5% of patients underwent surgery.
- Median follow-up was 64 months for the chemotherapy+CRS group vs 61.2 for the chemotherapy-alone group (P=.09).
- Patients who received CRS experienced improved median OS vs those treated with chemotherapy alone:
- 13.7 vs 10.8 months (P<.001>
- CRS was associated with prolonged OS in:
- Inverse probability of treatment weighting-adjusted analysis: HR, 0.63 (P<.001>
- Propensity score-matched analysis: HR, 0.61 (P<.0001>